BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9864084)

  • 1. Case report: possible neuroleptic malignant syndrome associated with olanzapine.
    Moltz DA; Coeytaux RR
    J Clin Psychopharmacol; 1998 Dec; 18(6):485-6. PubMed ID: 9864084
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine-induced neuroleptic malignant syndrome.
    Burkhard PR; Vingerhoets FJ; Alberque C; Landis T
    Arch Gen Psychiatry; 1999 Jan; 56(1):101-2. PubMed ID: 9892264
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome after the initiation of olanzapine.
    Levenson JL
    J Clin Psychopharmacol; 1999 Oct; 19(5):477-8. PubMed ID: 10505593
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neuroleptic malignant syndrome associated with olanzapine].
    García López MM; Ciprés L; de Cendra E; Vilalta Franch J
    Med Clin (Barc); 1999 Sep; 113(6):239. PubMed ID: 10472615
    [No Abstract]   [Full Text] [Related]  

  • 5. Atypical neuroleptic malignant syndrome associated with olanzapine.
    Reeves RR; Torres RA; Liberto V; Hart RH
    Pharmacotherapy; 2002 May; 22(5):641-4. PubMed ID: 12013364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
    Mujica R; Weiden P
    Am J Psychiatry; 2001 Apr; 158(4):650-1. PubMed ID: 11282706
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine and neuroleptic malignant syndrome.
    Tofler I
    Psychosomatics; 2002; 43(6):505-6; author reply 506. PubMed ID: 12444237
    [No Abstract]   [Full Text] [Related]  

  • 8. Manic symptoms induced by olanzapine.
    Lykouras L; Gournellis R; Angelopoulos E
    Eur Neuropsychopharmacol; 2001 Apr; 11(2):97-8. PubMed ID: 11313153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia associated with olanzapine monotherapy.
    Ananth J; Kenan J
    J Clin Psychiatry; 1999 Dec; 60(12):870. PubMed ID: 10665640
    [No Abstract]   [Full Text] [Related]  

  • 10. Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.
    Finkel B; Lerner A; Oyffe I; Rudinski D; Sigal M; Weizman A
    Int Clin Psychopharmacol; 1998 May; 13(3):133-5. PubMed ID: 9690981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypertriglyceridemia associated with olanzapine.
    Stoner SC; Dubisar BM; Khan R; Farrar CD
    J Clin Psychiatry; 2002 Oct; 63(10):948-9. PubMed ID: 12416606
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute dystonia with olanzapine.
    Landry P; Cournoyer J
    J Clin Psychiatry; 1998 Jul; 59(7):384. PubMed ID: 9714272
    [No Abstract]   [Full Text] [Related]  

  • 13. Olanzapine-induced neuroleptic malignant syndrome with mental retardation.
    Margolese HC; Chouinard G
    Am J Psychiatry; 1999 Jul; 156(7):1115-6. PubMed ID: 10401467
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia.
    Jackson RS
    Arch Gen Psychiatry; 2001 Jul; 58(7):706-7. PubMed ID: 11448379
    [No Abstract]   [Full Text] [Related]  

  • 15. Propranolol treatment of olanzapine-induced akathisia.
    Kurzthaler I; Hummer M; Kohl C; Miller C; Fleischhacker WW
    Am J Psychiatry; 1997 Sep; 154(9):1316. PubMed ID: 9286196
    [No Abstract]   [Full Text] [Related]  

  • 16. Recurrence of neuroleptic malignant syndrome with olanzapine treatment.
    Gheorghiu S; Knobler HY; Drumer D
    Am J Psychiatry; 1999 Nov; 156(11):1836. PubMed ID: 10553758
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine usage associated with neuroleptic malignant syndrome.
    Philibert RA; Adam LA; Frank FM; Carney-Doebbeling C
    Psychosomatics; 2001; 42(6):528-9. PubMed ID: 11815691
    [No Abstract]   [Full Text] [Related]  

  • 18. Olanzapine-induced neutropenia.
    Gajwani P; Tesar GE
    Psychosomatics; 2000; 41(2):150-1. PubMed ID: 10749954
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuropletic malignant syndrome and olanzapine.
    Sierra-Biddle D; Herran A; Diez-Aja S; Gonzalez-Mata JM; Vidal E; Diez-Manrique F; Vazquez-Barquero JL
    J Clin Psychopharmacol; 2000 Dec; 20(6):704-5. PubMed ID: 11106147
    [No Abstract]   [Full Text] [Related]  

  • 20. Ziprasidone alternative for olanzapine-induced hyperglycemia.
    Spivak B; Alamy SS; Jarskog LF; Sheitman BB; Lieberman JA
    Am J Psychiatry; 2002 Sep; 159(9):1606. PubMed ID: 12202289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.